These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15203873)

  • 1. Hematology morphology forum.
    Kansu E; Uner A; McCarthur JR
    Hematology; 2004 Apr; 9(2):157-8. PubMed ID: 15203873
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression.
    Kajal B; Chang H
    Blood; 2016 Mar; 127(12):1619. PubMed ID: 27462671
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.
    Athanasiou E; Kaloutsi V; Kotoula V; Hytiroglou P; Kostopoulos I; Zervas C; Kalogiannidis P; Fassas A; Christakis JI; Papadimitriou CS
    Am J Clin Pathol; 2001 Oct; 116(4):535-42. PubMed ID: 11601138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
    Abdalla S; May PC; Garimberti E; Naresh KN
    Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.
    Tasidou A; Roussou M; Terpos E; Kastritis E; Gkotzamanidou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Nikitas N; Anagnostou D; Dimopoulos MA
    Am J Hematol; 2012 Jul; 87(7):734-6. PubMed ID: 22565393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looks can be deceiving.
    Overbeek M; Goossens B; Vos JM
    Neth J Med; 2014 Apr; 72(3):149-53. PubMed ID: 24846929
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
    Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
    Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma with Auer-rod-like inclusions.
    Castoldi G; Piva N; Tomasi P
    Haematologica; 1999 Sep; 84(9):859-60. PubMed ID: 10477463
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematology problem: plasma cell leukemia in multiple myeloma.
    Parrish J
    Am J Med Technol; 1983 Apr; 49(4):263-4. PubMed ID: 6846391
    [No Abstract]   [Full Text] [Related]  

  • 10. [Non-excretory plasma cell myeloma (apropos of 2 new cases)].
    Menkes CJ; Herreman G; Preud'homme JL; Godeau P; Delbarre F
    Nouv Presse Med; 1972 Jan; 1(5):309-12. PubMed ID: 4551593
    [No Abstract]   [Full Text] [Related]  

  • 11. IgM multiple myeloma: pathologic evaluation of a rare entity.
    King RL; Howard MT; Hodnefield JM; Morice WG
    Am J Clin Pathol; 2013 Oct; 140(4):519-24. PubMed ID: 24045549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of chronic lymphocytic leukaemia and multiple myeloma: report of a case and review of the literature.
    Quaglino D; Paterlini P; De Pasquale A; Cretara G; Venturoni L
    Haematologica; 1982 Aug; 67(4):576-88. PubMed ID: 6815016
    [No Abstract]   [Full Text] [Related]  

  • 13. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
    Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
    Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of malignant plasma cells in the bone marrow and peripheral blood of patients with multiple myeloma.
    Brown RD; Ho PJ
    Methods Mol Biol; 2002; 179():85-91. PubMed ID: 11692875
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
    Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A
    Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow morphology in multiple myeloma.
    Kuriakose P; Das S; Mani A
    Indian J Cancer; 1995 Sep; 32(3):100-3. PubMed ID: 8772808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma.
    Coffey DG; Wu QV; Towlerton AMH; Ornelas S; Morales AJ; Xu Y; Green DJ; Warren EH
    Blood Cancer J; 2019 Sep; 9(10):77. PubMed ID: 31570697
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis versus differential diagnosis of multiple myeloma].
    Bessmel'tsev SS
    Vopr Onkol; 2004; 50(4):406-16. PubMed ID: 15605762
    [No Abstract]   [Full Text] [Related]  

  • 20. [Picture in Clinical Hematology].
    Rinsho Ketsueki; 2015 Jun; 56(6):575. PubMed ID: 26256864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.